Literature DB >> 8384030

Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.

M O Gearhart1, T B Sorg.   

Abstract

OBJECTIVE: To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders. CASE
SUMMARY: An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet. The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy. Laboratory results indicated hypomagnesemia, hypocalcemia, hypokalemia, and hypophosphatemia. After electrolyte supplementation and discontinuation of foscarnet, the symptoms resolved and laboratory indices returned to normal. DISCUSSION: Electrolyte disorders associated with foscarnet are reviewed. Severe hypomagnesemia occurred in this patient and published literature is highlighted. In addition, known and/or possible mechanisms of the disorders are discussed.
CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. Electrolytes must be monitored frequently during foscarnet therapy. Also, concomitant therapy with antianxiety medications that may mask the symptoms of electrolyte disorders should be undertaken with caution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384030     DOI: 10.1177/106002809302700304

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  13 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals.

Authors:  Elena Ramírez; Tomás Rossignoli; Armando J Campos; Raúl Muñoz; Claudia Zegarra; Hoi Tong; Nicolás Medrano; Alberto M Borobia; Antonio J Carcas; Jesús Frías
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

Review 3.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Renal magnification by EGF.

Authors:  David H Ellison
Journal:  Nephrol Dial Transplant       Date:  2008-02-25       Impact factor: 5.992

Review 5.  Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.

Authors:  Carlos G Musso; Waldo H Belloso; Richard J Glassock
Journal:  World J Nephrol       Date:  2016-01-06

6.  A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.

Authors:  M M Huycke; M T Naguib; M M Stroemmel; K Blick; K Monti; S Martin-Munley; C Kaufman
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 7.  Comparative tolerability of therapies for cytomegalovirus retinitis.

Authors:  S Walmsley; A Tseng
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 8.  Minimising the dosage-limiting toxicities of foscarnet induction therapy.

Authors:  D T Jayaweera
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

9.  Foscarnet alters antidiuretic hormone-mediated transport.

Authors:  B S Hoch; S J Shahmehdi; B M Louis; H I Lipner
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 10.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.